7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Cortexyme, Inc
(NASDAQ:CRTX) 

CRTX stock logo

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase I...

Founded: 2012
Full Time Employees: 37 (May 2021)
CEO: Casey Crawford Lynch  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Cortexyme Op Cashflow Per Share ttm
202208 202209 202210 202211 202212 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.17-1.86-1.55-1.24-0.93-0.62-0.310
Cortexyme Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.18-1.86-1.55-1.24-0.93-0.62-0.310
Cortexyme Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.511.031.542.052.563.083.59
Cortexyme (GAAP) P/E ratio ttm
202208 202209 202210 202211 202212 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1,654.01-1,417.73-1,181.44-945.15-708.86-472.58-236.290
Cortexyme P/B ratio ttm
202208 202209 202210 202211 202212 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 081.09162.18243.28324.37405.46486.55567.65
No extra charts and metrics for this ticker.